Method for isolating hepatitis C virus peptides

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C930S220000, C930S223000, C424S186100, C424S189100, C424S225100, C424S228100

Reexamination Certificate

active

07378234

ABSTRACT:
Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

REFERENCES:
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6150087 (2000-11-01), Chien
patent: 6413517 (2002-07-01), Sette et al.
patent: 2003/0162738 (2003-08-01), Egyed et al.
patent: A 1973/2000 (2000-11-01), None
patent: A 805/2001 (2001-05-01), None
patent: 0 468 520 (1991-07-01), None
patent: WO 92/03458 (1992-03-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/25601 (1994-11-01), None
patent: WO 95/12766 (1995-05-01), None
patent: WO 95/22317 (1995-08-01), None
patent: WO 95/25122 (1995-09-01), None
patent: WO 95/27733 (1995-10-01), None
patent: WO 95/27901 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/30721 (1997-08-01), None
patent: WO 98/15287 (1998-04-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 99/15259 (1999-04-01), None
patent: WO 99/33488 (1999-06-01), None
patent: WO 99/38528 (1999-08-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/63941 (1999-12-01), None
patent: WO 00/11186 (2000-03-01), None
patent: WO 00/23105 (2000-04-01), None
patent: WO 00/31542 (2000-06-01), None
patent: WO 00/44775 (2000-08-01), None
patent: WO 01/17551 (2001-03-01), None
patent: WO 01/21189 (2001-03-01), None
patent: WO 01/24822 (2001-04-01), None
patent: WO 01/54719 (2001-08-01), None
patent: WO 01/72782 (2001-10-01), None
patent: WO 01/78767 (2001-10-01), None
patent: WO 01/93903 (2001-12-01), None
patent: WO 01/93905 (2001-12-01), None
patent: WO 02/13857 (2002-02-01), None
patent: WO 02/32451 (2002-04-01), None
patent: WO 02/33127 (2002-04-01), None
patent: WO 02/053185 (2002-07-01), None
patent: WO 02/095027 (2002-11-01), None
patent: WO 03/047602 (2003-06-01), None
patent: WO 03/073097 (2003-09-01), None
patent: WO 2004/014936 (2004-02-01), None
patent: WO 2004/024182 (2004-03-01), None
Jung MC et al. T cell recognition of hepatitis B and C viral antigens. Eur J clin Invest. (Oct. 1994);24(10);641-50.
Koziel MH et al. Hepatisis C Virus (HCV)-Specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV. J Virol. Dec. 1993;67(12):7522-7532.
Koziel, et al. HCV-specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV. J Virol. 1993; 67(12):7522-7532.
Betts, et al. Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Hiscompatibility Complex Class I Haplotype. J Virol. 2000; 74(19):9144-9151.
Maecker, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Meth. 2001; 255(1-2):27-40.
“Aluminiumhydroxide,” Röempp, 10thEd., pp. 139-140, 2006 (in German).
Battegay et al., “Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules,”J. Virol., 69(4):2462-2470, 1995.
Bellentani et al., “Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery,”Microbes Infect., 2(14):1757-63, 2000.
Blake et al., “Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes,”J. Exp. Med., 184:121-130, 1996.
Chang et al., “Identification of HLA-A3 and B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C,”J. Immunol., 162:1156-1164, 1999.
Cho et al., “Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLK-NH2, via cell surface calreticulin,”Eur. J. Biochem., 266:878-885, 1999.
Diepolder et al., “Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection,”J. Virol., 71(8):6011-6019, 1997.
Duenas-Carrera et al., “Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids,”Biotechnol. Appl. Biochem., 35:205-212, 2002.
Farci and Purcell, “Clinical significance of hepatitis C virus genotypes and quasispecies,”Semin Liver Dis., 20(1):103-26, 2000.
Gruener et al., “Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus,”J. Virol., 75:5550-5558, 2001.
Heile et al., “Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates,”J. Virol., 74(15):6885-6892, 2000.
Hemmer et al., “Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology,”J. Immunol., 160:3631-3636, 1998.
Hemmer et al., “The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells,”J. Peptide Res., 52:338-345, 1998.
HLA-prevalence studies, In: HLA 1998, (Gjertson and Terasaki, eds.) American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas, pp. 103-263, 1998.
Hoffmann et al., “Mapping of Immunodominant CD4+ T Lymphocyte Epitopes of Hepatitis C Virus Antigens and Their Relevance During the Course if Chronic Infection,”Hepatology, 21(3):632-638, 1995.
Ibe et al., “Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B3501 in acute hepatitis,”J. Gen. Virol., 79:1735-1744, 1998.
Inchauspe and Feinstone, “Development of a heptatis C virus vaccine,”Clinics in Liver Disease, 7:243-259, 2003.
Keilholz et al., “Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy,”J. Immunother., 25(2):97-138, 2002.
Koziel et al., “Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV,”J. Virol., 67:7522-7532, 1993.
Koziel et al., “HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release,”J. Clin. Invest., 96:2311-2321, 1995.
Kurokohchi et al., “A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection,”J. Hepatology, 34:930-935, 2001.
Lamonaca et al., “Conserved Hepatitis C Virus Sequences Are Highly Immunogenic for CD4+ T Cells: Implications for Vaccine Development,”Hepatology, 30(4):1088-1098, 1999.
Lechmann and Liang, “Vaccine development for hepatitis C,”Seminars in Liver Disease, 20:211-226, 2000.
Leroux-Roels et al., “Lymphoproliferative Responses to Hepatitis C Virus Coes, E1, E2, and NS3 in Patients With Chronic Hepatitis C Infection Treated With Inte

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for isolating hepatitis C virus peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for isolating hepatitis C virus peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for isolating hepatitis C virus peptides will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2804043

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.